Curis, Inc. Share Price Nasdaq
Equities
US2312691015
Biotechnology & Medical Research
Sales 2024 * | 8.75M 730M | Sales 2025 * | 8.76M 731M | Capitalization | 76.62M 6.39B |
---|---|---|---|---|---|
Net income 2024 * | -48M -4B | Net income 2025 * | -53M -4.42B | EV / Sales 2024 * | 8.76 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 8.74 x |
P/E ratio 2024 * |
-1.94
x | P/E ratio 2025 * |
-2.67
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.82% |
Latest transcript on Curis, Inc.
Managers | Title | Age | Since |
---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 29/16/29 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 26/22/26 |
Chief Tech/Sci/R&D Officer | - | 03/22/03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kenneth Kaitin
BRD | Director/Board Member | 71 | 01/03/01 |
Martyn Greenacre
CHM | Chairman | 82 | 14/00/14 |
James Dentzer
CEO | Chief Executive Officer | 57 | 29/16/29 |
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |